ELRIG Drug Discovery 2022
)
Even relatively recently, many key proteins and processes in human disease have been considered “undruggable”. However, recent advances against targets such as the RNA spliceosome and KRAS G12C have started to re-define the concept of druggability and how we can deliver forefront medicines across a range of diseases. In this session, we will celebrate some of the recent advances in this space, describing the impact of synthetic and medicinal chemistry in delivering agents against challenging diseases. Importantly, the talks will share key lessons learnt, to assist future success against equally challenging targets and our panel of experienced medicinal chemists will discuss their own experiences, future directions and upcoming challenges.
Daniel Fordham from Oxford Nanopore Technologies will present in the 'Frontiers of chemistry applied to drug discovery' track and you can stop by our booth (B5) to discuss further.
